Pharmacologic Dose Testosterone to Treat Castration Resistant Prostate Cancer: Mechanisms of Action and Drivers of Response

Abstract

Purpose: Single-arm studies have demonstrated preliminary signs of efficacy for intermittent pharmacologic dose testosterone (i.e. Bipolar Androgen Therapy; BAT) in treating advanced prostate cancer. In this project, we will conduct detailed molecular assessments on biospecimens (i.e. blood, metastatic tissue) from men receiving BAT to determine somatic and germline factors that predict for response/resistance. We will also evaluate additional PDT-based regimens (e.g. combinatorial treatments) in preclinical models. Scope: This annual technical progress report details progress made during the first year of funding for this project (30 Sep 2017 1 Oct 2018). Major Findings: During Year 2 we have continued to focus on biospecimen acquisition from men enrolled to a Phase II study testing BAT vs. enzalutamide. Results from correlative studies are not available at this time. Preclinical studies are ongoing.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2018
Accession Number
AD1074302

Entities

People

  • Michael T Schweizer

Organizations

  • University of Washington

Tags

DTIC Thesaurus Topics

  • Acquisition
  • Blood
  • Body Weight
  • Carcinoma
  • Cell Physiological Processes
  • Cells
  • Chemistry
  • Chemotherapy
  • Colon Cancer
  • Crystal Structure
  • Diseases And Disorders
  • Genetics
  • Genomic Instability
  • Health Services
  • Hormones
  • Liquid Chromatography
  • Medical Personnel
  • Neoplasms
  • Oncology
  • Prostate Cancer
  • Therapy
  • Tissues
  • United States

Fields of Study

  • Medicine
  • Physics

Readers

  • Clinical Trial Research.
  • Prostate Cancer Biology.